/COCH
COCH Stock - Envoy Medical, Inc.
Healthcare|Medical - DevicesNASDAQ
$0.73+4.67%
+$0.03 (+4.67%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.37
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+718.9%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COCH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.73 – $0.74
TARGET (TP)$6.00
STOP LOSS$0.67
RISK/REWARD1:84.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.07
52W High$1.91
52W Low$0.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $225,000 | $316,000 | $237,000 | $310,000 | N/A |
| Gross Profit | $-517,000 | $-473,000 | $-261,000 | $-459,000 | N/A |
| Gross Margin | -229.8% | -149.7% | -110.1% | -148.1% | N/A |
| Operating Income | $-19,256,000 | $-18,359,000 | $-8,706,000 | $-6,871,000 | $-701 |
| Net Income | $-20,795,000 | $-29,922,000 | $-15,923,000 | $-8,675,000 | $-701 |
| Net Margin | -9242.2% | -9469.0% | -6718.6% | -2798.4% | N/A |
| EPS | $-1.49 | $-2.54 | $-1.57 | $-1.05 | $0.00 |
Company Overview
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 1060.1% Upside
Now
$9
Low
$9
Average
$9
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 24th 2024 | Ascendiant Capital Markets | Initiation | Buy | $8.5 |
Earnings History & Surprises
COCHBeat Rate
13%
Last 8 quarters
Avg Surprise
-26.0%
EPS vs Estimate
Beats / Misses
1/7
Last 12 quarters
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q1 24
-31.1%
$-0.25vs$-0.19
Q2 24
-68.4%
$-0.32vs$-0.19
Q3 24
-12.5%
$-0.27vs$-0.24
Q4 24
-37.0%
$-0.37vs$-0.27
Q1 25
-36.4%
$-0.45vs$-0.33
Q2 25
+17.1%
$-0.29vs$-0.35
Q3 25
-10.3%
$-0.32vs$-0.29
Q4 25
-29.6%
$-0.35vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.28 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.27 | $-0.35 | -29.6% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-0.29 | $-0.32 | -10.3% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.35 | $-0.29 | +17.1% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.33 | $-0.45 | -36.4% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.27 | $-0.37 | -37.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.19 | $-0.32 | -68.4% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.19 | $-0.25 | -31.1% | ✗ MISS |
Q4 2023 | Nov 17, 2023 | — | $0.13 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.68 | — | — |
Q2 2023 | May 15, 2023 | — | $0.02 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.22 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.12 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.15 | — | — |
Q2 2022 | May 16, 2022 | — | $0.23 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.09 | — | — |
Q4 2021 | Dec 30, 2021 | — | $0.10 | — | — |
Q3 2021 | Aug 17, 2021 | — | $0.01 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.04 | — | — |
Latest News
Envoy Medical Announces Its Pivotal Clinical Trial For Acclaim Cochlear Implant Reaches Midway Point Of Study's Full Enrollment Program
➖ NeutralBenzinga•Dec 18, 2025, 01:12 PM•Also:
Envoy Medical Issued Australian Patent No. 2022229818 Titled "Cochlear Implant System With Improved Input Signal-To-Noise Ratio"
📈 PositiveBenzinga•Dec 16, 2025, 01:14 PM•Also:
Envoy Medical Announces Completion Of First Set Of Activations In Final Stage Of Pivotal Clinical Study For Investigational Fully Implanted Acclaim Cochlear Implant
📈 PositiveBenzinga•Dec 10, 2025, 01:11 PM•Also:
Envoy Medical Announces USPTO Patent Issuance Advancing Fully Implanted Hearing Technology
📈 PositiveBenzinga•Nov 20, 2025, 01:10 PM
Envoy Medical Says All 10 Patients In First Stage Of Acclaim Cochlear Implant Clinical Trial Have Completed Six-Month Follow Up Visits
📈 PositiveBenzinga•Nov 18, 2025, 01:02 PM•Also:
Envoy Medical Q3 EPS $(0.35) Misses $(0.28) Estimate, Sales $42.000K Miss $70.000K Estimate
📉 NegativeBenzinga•Nov 10, 2025, 01:15 PM
Envoy Medical Enrolls First Three Participants In Final Stage In Pivotal Clinical Study Of Full Implanted Acclaim Cochlear Implant
📈 PositiveBenzinga•Nov 4, 2025, 01:11 PM•Also:
Envoy Medical Granted Nasdaq Extension Until February 23, 2026 To Regain Full Compliance
➖ NeutralBenzinga•Oct 27, 2025, 12:12 PM
Envoy Medical shares are trading lower after the company announced a $4 million registered direct offering and concurrent private placement of stock and warrants at $1.33 per share.
📉 NegativeBenzinga•Oct 8, 2025, 01:13 PM
Envoy Medical Announced A $4M Registered Direct Offering And Concurrent Private Placement Of Stock And Warrants At $1.33 Per Share
➖ NeutralBenzinga•Oct 8, 2025, 11:04 AM
Envoy Medical shares are trading higher after the company announced it received FDA approval to expand its clinical trial for the fully implanted Acclaim cochlear implant to the final stage based on 3-month data from the first 10 patients
📈 PositiveBenzinga•Oct 7, 2025, 03:39 PM•Also:
EXCLUSIVE: Envoy Medical Tells Benzinga The Company Expects To Complete Full Enrollment By Early Q1 2026 And Is Moving Its Timelines Up Three To Six Months, Cutting Its Anticipated Capital Needs By $10M-$15M
📈 PositiveBenzinga•Oct 7, 2025, 11:45 AM
EXCLUSIVE: Envoy Medical Tells Benzinga Co. Received FDA Approval To Expand Its Clinical Trial For The Fully Implanted Acclaim Cochlear Implant To The Final Stage Based On 3-Month Data From The First 10 Patients
📈 PositiveBenzinga•Oct 7, 2025, 11:45 AM•Also:
Envoy Medical Announces It Is Scaling Its Commercialization Planning For The Company's Breakthrough Investigational Acclaim Fully Implanted Cochlear Implant As Pivotal Trial Progresses
📈 PositiveBenzinga•Sep 24, 2025, 12:03 PM•Also:
Envoy Medical shares are trading lower after the company announced a $2.5 million registered direct offering of 1,908,402 shares at $1.31 per share.
📉 NegativeBenzinga•Sep 22, 2025, 06:52 PM
Envoy Medical Announces $2.5M Registered Direct Offering Of 1,908,402 Shares At $1.31/Share
➖ NeutralBenzinga•Sep 22, 2025, 12:08 PM
Envoy Medical Secures European Patent for Fully Implanted Cochlear System, Strengthening IP Ahead of Acclaim Launch
📈 PositiveBenzinga•Sep 19, 2025, 12:06 PM•Also:
Envoy Medical Issued Four Global Patents
📈 PositiveBenzinga•Sep 9, 2025, 12:13 PM
Envoy Medical Reports Safety Milestone In Pivotal Trial For Fully Implanted Cochlear Implant, Remains On Track For FDA Submission
📈 PositiveBenzinga•Sep 3, 2025, 12:13 PM•Also:
EXCLUSIVE: Envoy Medical Tells Benzinga 'Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversion'
📈 PositiveBenzinga•Aug 26, 2025, 11:45 AM
Frequently Asked Questions about COCH
What is COCH's current stock price?
Envoy Medical, Inc. (COCH) is currently trading at $0.73 per share. The stock has moved +4.67% today.
What is the analyst price target for COCH?
The average analyst price target for COCH is $6.00, based on 1 analyst.
What sector is Envoy Medical, Inc. in?
Envoy Medical, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is COCH's market cap?
Envoy Medical, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does COCH pay dividends?
No, Envoy Medical, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADGM
Adagio Medical Holdings, Inc.
$1.03
Mkt Cap: $0.0B
ADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.47
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
HCTI
Healthcare Triangle, Inc.
$1.93
Mkt Cap: $0.0B
IRIX
IRIDEX Corporation
$1.00
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.32
Mkt Cap: $0.0B
VSEE
VSee Health, Inc.
$0.44
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$1.97
Mkt Cap: $0.0B
Explore stocks similar to COCH for comparison